The treatment outcomes and influencing factors in rifampicin-resistant pulmonary tuberculosis patients in Sichuan Province, 2017-2023

doi:10.20199/j.issn.1672-2302.2026.03.008

Abstract

Abstract:

Objective To analyze the registration and medication status, treatment outcome and influencing factors among patients with rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Sichuan Province. Methods The data of RR-PTB patients registered in Sichuan Province from 2017 to 2023 was obtained from the Chinese Disease Prevention and Control Information System, with the registration and treatment outcomes of these patients analyzed. Joinpoint regression model analysis was performed to identify the changing trends of related indicators, and multivariate logistic regression analysis was applied to determine the influencing factors of successful treatment. Results From 2017 to 2023, a total of 4 561 RR-PTB patients were registered in Sichuan Province, with a registration rate of 0.78/100 000. The registration rate showed an overall upward trend (AAPC=13.760%, 95%CI: 4.453% to 24.065%, t=3.545, P<0.05); The enrollment rate of RR-PTB patients in treatment was 91.78%, which presented an overall increasing trend (AAPC=5.240%, 95%CI: 4.050% to 6.368%, t=5.574, P<0.001). The successful treatment rate of RR-PTB patients was 78.28%. Multivariate logistic regression analysis showed that RR-PTB patients with characteristics of male sex(OR=1.379, 95%CI: 1.142 to 1.665), ethnic minority status (OR=2.652, 95%CI:1.850 to 3.803), migrant household registration (OR=2.056, 95%CI: 1.628 to 2.597), residence in western Sichuan (OR=2.006, 95%CI: 1.389 to 2.897), retreatment history (OR=1.191, 95%CI: 1.018 to 1.394), multidrug resistance (OR=1.278, 95%CI: 1.082 to 1.508), and quasi-extensive/extensive resistance (OR=1.595, 95%CI: 1.104 to 2.304) had a lower treatment success rate. Patients with PTB who were in the 15-39 age group (OR=0.375, 95%CI: 0.190 to 0.743), whose occupations were student (OR=0.348, 95%CI: 0.216 to 0.560) or worker (OR=0.398, 95%CI: 0.177 to 0.856), had a higher treatment success rate. Conclusion The registration rate and treatment enrollment rate of RR-PTB patients in Sichuan Province have continued to increase, yet there are differences in population and regions. These findings suggest that it is necessary to strengthen precise prevention and full-course management for male, ethnic minorities, floating population, retreated patients and those residing in western Sichuan, as well as to optimize resource allocation and continuously improve the levels of standardized diagnosis, treatment and case management.

Key words: Tuberculosis, Rifampicin resistance, Treatment outcome, Influencing factors, Sichuan Province

CLC Number:

R521

ZHONG Yin, XIA Lan, LI Yunkui, XIONG Yan, WANG Danxia, LI Ting. The treatment outcomes and influencing factors in rifampicin-resistant pulmonary tuberculosis patients in Sichuan Province, 2017-2023[J]. Journal of Tropical Diseases and Parasitology, 2026, 24(3): 172-176,封三.

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 23

[1]	孙慧娟, 苏伟, 陈伟. 利福平耐药结核病患者不良治疗结局及其影响因素研究进展[J]. 结核与肺部疾病杂志, 2024, 5(6):573-582.
[2]	World Health Organization. Global tuberculosis report 2025[R/OL]. (2025-11-12)[2026-03-21]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2025.
[3]	阮云洲, 苏伟, 张慧, 等. 我国利福平耐药结核病防治的历史沿革及展望[J]. 中国防痨杂志, 2024, 46(10):1166-1170.
[4]	四川省统计局. 国民经济和社会发展统计公报[R/OL]. [2026-03-21]. https://tjj.sc.gov.cn/scstjj/c112126/list.shtml.
[5]	李婷, 刘双, 王丹霞, 等. 2007-2021年四川省儿童肺结核登记情况及流行病学特征分析[J]. 疾病监测, 2024, 39(9):1115-1121.
[6]	赵雁林, 陈明亭. 中国结核病防治工作技术指南[M]. 北京: 人民卫生出版社, 2021:173.
[7]	国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国肺结核预防控制工作技术规范(2020年版)的通知[A/OL].(2020-04-02)[2026-03-21]. http://tb.chinacdc.cn/ggl/202004/P020200414515703939844.pdf.
[8]	杜雨华, 冯亚娟, 雷宇, 等. 广州市“十二五”与“十三五”期间利福平耐药肺结核患者发现与治疗情况分析[J]. 中国防痨杂志, 2024, 46(6):678-686.
[9]	李玉红, 梅金周, 苏伟, 等. 2015-2021年全国65岁及以上老年利福平耐药肺结核患者治疗转归及影响因素分析[J]. 中国防痨杂志, 2025, 47(4):408-415.
[10]	四川省卫生健康委员会,四川省发展和改革委员会,四川省教育厅, 等. 关于印发四川省遏制肺结核行动实施方案(2019-2022年)的通知:川卫发〔2019〕48号[A/OL]. (2019-11-11)[2026-03-21]. https://wsjkw.sc.gov.cn/scwsjkw/zcwj11/2019/12/2/a1e36bc971a54f5893fe276670f1d2d2.shtml.
[11]	雷蓉蓉, 汪清雅, 吴成果, 等. 2018-2022年重庆市利福平耐药肺结核患者治疗转归及影响因素分析[J]. 热带病与寄生虫学, 2025, 23(6):353-357.
[12]	沙小兰, 田晓福, 田晓梅, 等. 2018-2022年宁夏回族自治区耐多药/利福平耐药肺结核患者治疗转归及其影响因素分析[J]. 结核与肺部疾病杂志, 2025, 6(6):710-716.
[13]	孙慧娟, 刘小秋, 苏伟, 等. 2017-2021年中国9个省份利福平耐药结核病患者不良治疗结局发生情况及影响因素分析[J]. 中华流行病学杂志, 2025, 46(2):188-195.
[14]	Kyrbashov B, Kulzhabaeva A, Kadyrov A, et al. Time to treatment and risk factors for unsuccessful treatment outcomes among people who started second-line treatment for rifampicin-resistant or multi-drug-resistant tuberculosis in the Kyrgyz Republic, 2021[J]. TropicalMed, 2023, 8(8):407. doi: 10.3390/tropicalmed8080407 URL
[15]	Salari N, Kanjoori AH, Hosseinian-Far A, et al. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis[J]. Infect Dis Poverty, 2023, 12(1):57. doi: 10.1186/s40249-023-01107-x pmid: 37231463
[16]	邹莉萍, 陈晴, 唐先珍, 等. 耐多药/利福平耐药结核病患者合并外周血CD4⁺T淋巴细胞降低的临床特征及危险因素分析[J]. 中国热带医学, 2024, 24(5):537-541. doi: 10.13604/j.cnki.46-1064/r.2024.05.07
[17]	Jian SS, Wang Y, Wang DF, et al. Patient mobility and travel distance to receive drug-resistant tuberculosis treatment, and their associations with loss to follow-up in Guizhou Province, China[J]. BMC Infect Dis, 2025, 25(1):1513. doi: 10.1186/s12879-025-11560-8
[18]	Xia XL, Huang FL, Wang Y, et al. What are the real-life dilemmas and facilitators of medication adherence of patients with drug-resistant tuberculosis: a qualitative exploration of patient perspectives[J]. Infect Drug Resist, 2025, 18:5351-5364. doi: 10.2147/IDR.S554556 pmid: 41127147
[19]	Robsky KO, Isooba D, Nakasolya O, et al. Characterization of geographic mobility among participants in facility-and community-based tuberculosis case finding in urban Uganda[J]. PLoS One, 2021, 16(5):e0251806. doi: 10.1371/journal.pone.0251806 URL
[20]	金夏芸. 新发与复治结核病患者药物治疗策略的比较研究[J]. 现代诊断与治疗, 2024, 35(11):1714-1716.
[21]	Nasiri MJ, Amiri M, Cheraghi M, et al. 15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB[J]. IJTLD Open, 2025, 2(4):187-198. doi: 10.5588/ijtldopen.24.0620 pmid: 40226134
[22]	Salaam-Dreyer Z, Streicher EM, Sirgel FA, et al. Rifampicin-monoresistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from khayelitsha,south Africa[J]. Antimicrob Agents Chemother, 2021, 65(11):e00364-e00321.
[23]	四川省疾病预防控制局, 四川省卫生健康委员会, 四川省发展和改革委员会, 等. 关于印发《四川省肺结核防治规划(2025-2030年)》的通知:川疾控局发〔2025〕11号[A/OL]. (2025-12-11)[2026-03-21]. https://wsjkw.sc.gov.cn/scwsjkw/qtwj/2025/12/16/dafcc259147943f3970b1142b8c15d9b.shtml.

年份	常住人口（万人）	RR-PTB登记患者（例）	RR-PTB登记率（/10万）
2017	8 302	349	0.42
2018	8 341	545	0.65
2019	8 375	622	0.74
2020	8 371	597	0.71
2021	8 372	861	1.03
2022	8 374	614	0.73
2023	8 368	973	1.16
合计		4 561	0.78

年份	登记患者（例）	纳入治疗患者（例）	纳入治疗率（%）	治疗转归情况（例）						成功治疗患者（例）	成功治疗率（%）
年份	登记患者（例）	纳入治疗患者（例）	纳入治疗率（%）	治愈	完成治疗	治疗失败	死亡	失访	未评估	成功治疗患者（例）	成功治疗率（%）
2017	349	258	73.93	80	121	1	21	11	24	201	77.91
2018	545	436	80.00	119	214	5	44	9	45	333	76.38
2019	622	558	89.71	143	283	0	69	3	60	426	76.34
2020	597	551	92.29	185	244	7	51	15	49	429	77.86
2021	861	824	95.70	330	352	5	68	23	46	682	82.77
2022	614	606	98.70	285	214	0	62	12	33	499	82.34
2023	973	953	97.94	440	267	4	83	6	153	707	74.19
合计	4 561	4 186	91.78	1 582	1 695	22	398	79	410	3 277	78.28

特征	纳入治疗患者		成功治疗患者
特征	例数（例）	构成比（%）	例数（例）	成功治疗率（%）
性别
男性	3 001	71.69	2 300	76.64
女性	1 185	28.31	977	82.45
年龄（岁）
<15	70	1.67	52	74.29
15~39	1 453	34.71	1 214	83.55
40~64	2 020	48.26	1 558	77.13
≥65	643	15.36	453	70.45
民族
汉族	3 509	83.83	2 869	81.76
少数民族	677	16.17	408	60.27
职业
农民	2 641	63.09	1 991	75.39
家务及待业	652	15.58	538	82.52
学生	279	6.67	244	87.46
离退人员	151	3.61	105	69.54
工人	87	2.08	80	91.95
其他	376	8.98	319	84.84
户籍类型
本地	3 735	89.23	2 962	79.30
流动	451	10.77	315	69.84
地区
川中	979	23.39	815	83.25
川南	1 095	26.16	877	80.09
川东北	1 329	31.75	1 099	82.69
川西	783	18.71	486	62.07
治疗分类
初治	2 292	54.75	1 852	80.80
复治	1 894	45.25	1 425	75.24
耐药类型
利福平单耐药	1 969	47.04	1 543	78.36
耐多药	2 022	48.30	1 586	78.44
准广泛/广泛耐药	195	4.66	148	75.90
化疗方案
长程	3 893	93.00	3 038	78.04
短程	164	3.92	142	86.59
其他	129	3.08	97	75.19
是否重点人群
重点人群	589	14.07	482	81.83
非重点人群	3 597	85.93	2 795	77.70

变量	β值	${\mathit{S}}_{\stackrel{-}{\mathit{x}}}$	Wald χ²值	P值	OR（95%CI）值
性别
女性					1.000
男性	0.322	0.096	11.170	<0.05	1.379（1.142~1.665）
年龄（岁）
<15					1.000
15~39	-0.980	0.349	7.907	<0.05	0.375（0.190~0.743）
40~64	-0.436	0.362	1.448	>0.05	0.647（0.318~1.315）
≥65	0.037	0.371	0.010	>0.05	1.038（0.502~2.148）
民族
汉族					1.000
少数民族	0.975	0.184	28.137	<0.001	2.652（1.850~3.803）
职业
农民					1.000
家务及待业	-0.128	0.119	1.145	>0.05	0.880（0.696~1.112）
学生	-1.056	0.244	18.809	<0.001	0.348（0.216~0.560）
离退人员	0.092	0.195	0.220	>0.05	1.096（0.747~1.608）
工人	-0.944	0.403	5.503	<0.05	0.398（0.177~0.856）
其他	-0.662	0.163	16.501	<0.001	0.516（0.375~0.710）
户籍类型
本地					1.000
流动	0.721	0.119	36.587	<0.001	2.056（1.628~2.597）
地区
川中					1.000
川南	0.051	0.118	0.184	>0.05	1.052（0.834~1.327）
川东北	-0.084	0.117	0.512	>0.05	0.919（0.730~1.157）
川西	0.696	0.188	13.778	<0.001	2.006（1.389~2.897）
治疗分类
初治					1.000
复治	0.175	0.080	4.763	<0.05	1.191（1.018~1.394）
耐药类型
利福平单耐药					1.000
耐多药	0.245	0.085	8.380	<0.05	1.278（1.082~1.508）
准广泛/广泛耐药	0.467	0.188	6.190	<0.05	1.595（1.104~2.304）